PeptiDream Announces Collaboration, License Agreement with Lilly
PeptiDream
(PeptiDream)(TOKYO:4587), announced that they have entered into a
Collaboration and License Agreement with US-based Eli Lilly and Company
(Lilly)(NYSE: LLY) on 19 December 2013. Under the agreement, PeptiDream
will identify macrocyclic peptides as potential drug candidates for
disease targets being pursued by Lilly. PeptiDream will leverage its
proprietary Peptide Discovery Platform System (PDPS) technology for
translational synthesis, selection, and screening of nonstandard
macrocyclic peptides, and Lilly will be responsible for any subsequent
research and development as pharmaceutical candidates.
Under the terms of the Agreement, PeptiDream will receive an undisclosed
upfront payment, research funding and milestone payments upon the
successful achievement of certain development milestones.
Posted-In: News Contracts Management Global
